Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8718278 | Apollo Medicine | 2016 | 7 Pages |
Abstract
The type of ESBL enzyme produced and the site and severity of infection are important considerations in determining antimicrobial therapy. Therefore, active surveillance for ESBL-producing organisms is critical to describe fully the local epidemiology of a given institution and/or referring centres; currently, the carbapenems, that is, imipenem and meropenem, are the only class of antimicrobials that have consistently been effective against ESBL-producing K. pneumoniae.
Related Topics
Health Sciences
Medicine and Dentistry
Emergency Medicine
Authors
P.K. Panda, Niharika Jhon, Shweta Sao,